2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexose | 73174-68-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexose
• 英文别名: 4-Deoxy-N-(trifluoracetyl)daunosamin；2,2,2-trifluoro-N-[(2R,4R,6S)-2-hydroxy-6-methyloxan-4-yl]acetamide
• CAS: 73174-68-2
• 化学式: C₈H₁₂F₃NO₃
• 分子量: 227.183
• InChiKey: ORWGAJSCNJBAIN-KVQBGUIXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  methyl 2,3,4,6-tetradeoxy-3-trifluoroacetamido-α-L-threo-hexopyranoside 在 溶剂黄146 作用下， 反应 2.5h， 以94%的产率得到2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexose
  参考文献：
  名称：

  Baer, Hans H.; Hanna, Hanna R., Canadian Journal of Chemistry, 1980, vol. 58, p. 1751 - 1758

  摘要：

  DOI：

文献信息

• Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
  申请人：Toxinvent Oü

  公开号：US10668166B2

  公开（公告）日：2020-06-02

  The present invention relates to novel anthracycline derivatives comprising two oxazolidine cycles and the preparation of said anthracycline derivatives. Furthermore, antibody-drug conjugates (ADCs) comprising the novel anthracycline derivatives and the use of such ADCs in the prevention and treatment of cancer are disclosed.

  本发明涉及包含两个噁唑烷循环的新型蒽环类衍生物以及上述蒽环类衍生物的制备方法。此外，本发明还公开了包含新型蒽环类衍生物的抗体-药物共轭物（ADCs）以及这种 ADCs 在预防和治疗癌症中的用途。
• ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT
  申请人：Toxinvent Oü

  公开号：EP3464294B1

  公开（公告）日：2022-07-13
• ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT
  申请人：Toxinvent Oü

  公开号：US20190262464A1

  公开（公告）日：2019-08-29

  The present invention relates to novel anthracycline derivatives comprising two oxazolidine cycles and the preparation of said anthracycline derivatives. Furthermore, antibody-drug conjugates (ADCs) comprising the novel anthracycline derivatives and the use of such ADCs in the prevention and treatment of cancer are disclosed.